Bypassing Agents + FVIII Replacement
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hemophilia A
Conditions
Hemophilia A
Trial Timeline
May 26, 2015 → Mar 31, 2017
NCT ID
NCT02476942About Bypassing Agents + FVIII Replacement
Bypassing Agents + FVIII Replacement is a pre-clinical stage product being developed by Roche for Hemophilia A. The current trial status is completed. This product is registered under clinical trial identifier NCT02476942. Target conditions include Hemophilia A.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02476942 | Pre-clinical | Completed |
Competing Products
20 competing products in Hemophilia A
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Emicizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Emicizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Emicizumab + rFVIIa + aPCC | Chugai Pharmaceutical | Phase 3 | 77 |
| Human Coagulation Factor VIII | Chugai Pharmaceutical | Phase 3 | 77 |
| Emicizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Emicizumab + Factor VIII (FVIII) | Chugai Pharmaceutical | Phase 3 | 77 |
| Emicizumab | Roche | Phase 3 | 77 |
| HEMLIBRA | Johnson & Johnson | Pre-clinical | 23 |
| Emicizumab | Roche | Phase 3 | 77 |
| Emicizumab | Roche | Approved | 85 |
| Emicizumab | Roche | Phase 3 | 77 |
| SPK-8011QQ | Roche | Phase 1/2 | 41 |
| NXT007 | Roche | Phase 1/2 | 41 |
| Emicizumab Injection | Roche | Phase 2 | 52 |
| PF-06741086 + PF-06741086 + PF-06741086 + PF-06741086 | Pfizer | Phase 2 | 51 |
| Nonacog Alfa (Genetical Recombination) | Pfizer | Pre-clinical | 22 |
| Refacto AF | Pfizer | Pre-clinical | 22 |
| PF-06838435/ fidanacogene elaparvovec | Pfizer | Phase 3 | 76 |
| ReFacto AF | Pfizer | Phase 3 | 76 |
| Nonacog alfa + Nonacog alfa | Pfizer | Phase 3 | 76 |